Computational design of ideotypically modulated pharmacoeffectors for selective cell treatment

Abstract

In system and method embodiments, an embodiment includes the collection, input, and organization of target nucleotide source or sources; the identification of potential target sequences for ideotypically modulated pharmacoeffectors (IMP); the exclusion, prioritization, or deprioritization of target sequences on the basis of undesirable binding for ideotypically modulated pharmacoeffectors (IMP); and/or the design of targeting sequences on the basis of reverse complementarity or sequence complementarity. IMPs are designed for optimal use in respective applications, including cancers, autoimmune diseases, infectious diseases, cellular diseases, and other applications.

Dependencies are inferred from the claim text.